Researchers receive $9M NCI grant for imaging tech in clinical trials

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

July 25, 2025

Vol.51 No.29

By Richard T. Lee

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

Ohio State launches pancreatic cancer trial via telehealth

The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.

July 03, 2025

Vol.51 No.26

Clinical Roundup

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Researchers receive $9M NCI grant for imaging tech in clinical trials

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Imaging’s ride to the bottom in clinical trials—and why it matters now

Ohio State launches pancreatic cancer trial via telehealth

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

Renew today!

Subscriber content

Never miss an issue!

Login